About this episode

This episode discusses the implications of MASLD and MASH, focusing on screening methods and recent clinical trials.

MASLD affects nearly one in three adults worldwide, yet many patients remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? When is a FIB-4 enough, and when should we move to elastography or hepatology referral? And are we finally entering an era where we can meaningfully treat MASH? In this Beyond Journal Club episode, we unpack the evolving language of steatotic liver disease and take a close look at two major trials: MAESTRO-NASH studying resmetirom, the first FDA-approved liver-directed therapy for MASH, and ESSENCE, evaluating semaglutide in biopsy-confirmed disease. Along the way, we explore what these biopsy-based histologic endpoints really mean, why placebo responses were surprisingly high , and whether improvements in steatohepatitis and fibrosis will ultimately translate into better clinical outcomes for patients. This episode is for clinicians trying to understand where the field is headed, which patients deserve closer attention, and how metabolic liver disease is increasingly becoming part of everyday primary care and hospital medicine. 🔹 Sponsor: Oakstone CME Use the code "CORE325" for 25%…

People in this episode

Host: Core IM Team

Topics covered

• MASLD
• MASH
• steatotic liver disease
• screening for fibrosis
• clinical outcomes
• metabolic liver disease

Keywords

• elastography
• MASLD
• MASH
• FIB-4
• MAESTRO-NASH
• ESSENCE
• liver disease
• clinical trials
• biopsy
• treatment

Sponsors

Oakstone CME

Mentioned in this episode

Products: resmetirom, semaglutide

More episodes of Core IM | Internal Medicine Podcast

• #212 Top 10 Highlights of the New Lipid Guidelines · July 15, 2026 · 24 min
• #210 HTN in Dialysis: 5 Pearls Segment · June 17, 2026 · 26 min

Explore listener stats, chart rankings, contacts and more on the Core IM | Internal Medicine Podcast podcast page.